By: IPP Bureau
Last updated : February 17, 2022 10:58 am
Dr. Peter Houghton will lead the research collaboration for GCCRI and is widely regarded as a leading expert in pediatric cancer research and in the development of novel approaches to treating childhood cancers
Lantern Pharma announced that it is expanding opportunities for its portfolio of drug candidates and A.I. drug discovery platform into additional rare pediatric cancers through a collaboration with The Greehey Children’s Cancer Research Institute (GCCRI), at the University of Texas Health Science Centre at San Antonio. GCCRI is one of only two research institutions in the United States focused exclusively on pediatric cancer research and therapy development.
The research collaboration will focus on further validating findings from RADR regarding the effectiveness of Lantern's LP-184 and LP-284 in genomically-defined pediatric cancers, including several without any effective therapeutic approach. The collaboration will initially leverage GCCRI's paediatric tumor research models and knowledge base to advance Lantern's drug candidate, LP-184, for the treatment of rare paediatric cancers including rhabdomyosarcoma, Ewing sarcoma, MRT (malignant rhabdoid tumor), Wilms tumor, and ATRT (atypical teratoid rhabdoid tumor).
"Transforming the pace at which we develop new therapies for pediatric and rare cancers requires that we make constant use of data, advanced approaches and models, and machine learning to maximize the therapeutic potential of our portfolio. This collaboration with Dr. Houghton and his lab will help us potentially validate multiple new pediatric indications and also generate insights that may lead to new therapies, and all of this is being done at a fraction of the cost of traditional drug development," says Lantern Pharma's, President and CEO, Panna Sharma.